Inspire Md, Inc. NSPR
We take great care to ensure that the data presented and summarized in this overview for InspireMD, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NSPR
View all-
Nantahala Capital Management, LLC New Canaan, CT2.21MShares$5.59 Million0.35% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.13MShares$5.4 Million0.13% of portfolio
-
Marshall Wace, LLP London, X01.86MShares$4.71 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.38MShares$3.49 Million0.31% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA904KShares$2.29 Million5.02% of portfolio
-
Pura Vida Investments, LLC New York, NY451KShares$1.14 Million0.83% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny400KShares$1.01 Million0.0% of portfolio
-
Affiance Financial, LLC184KShares$464,8770.12% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT104KShares$263,3240.04% of portfolio
-
Morgan Stanley New York, NY89.5KShares$226,4190.0% of portfolio
Latest Institutional Activity in NSPR
Top Purchases
Top Sells
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at NSPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Michael Berman Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
61,249
+25.0%
|
$61,249
$1.38 P/Share
|
|
Jun 05
2024
|
Paul Stuka Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
87,500
+20.66%
|
$87,500
$1.38 P/Share
|
|
May 28
2024
|
Thomas J Kester Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
30,625
+8.57%
|
$30,625
$1.38 P/Share
|
|
May 28
2024
|
Gary S Roubin Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
30,625
+5.75%
|
$30,625
$1.38 P/Share
|
|
Jan 23
2024
|
Michael Berman Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,032
+11.12%
|
-
|
|
Jan 23
2024
|
Paul Stuka Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,548
+12.26%
|
-
|
|
Jan 23
2024
|
Marvin Slosman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
563,499
+23.33%
|
-
|
|
Jan 23
2024
|
Gary S Roubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,032
+5.8%
|
-
|
|
Jan 23
2024
|
Craig Shore CFO and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
238,625
+21.34%
|
-
|
|
Jan 23
2024
|
Kathryn Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,032
+11.89%
|
-
|
|
Jan 23
2024
|
Andrea Tommasoli Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238,625
+32.52%
|
-
|
|
Jan 23
2024
|
Shane Thomas Gleason Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238,625
+31.69%
|
-
|
|
Jan 23
2024
|
Patrick Verta EVP Clinical/Medical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
85,720
+27.28%
|
-
|
|
Jan 23
2024
|
Thomas J Kester Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,032
+8.93%
|
-
|
|
Jan 02
2024
|
Gary S Roubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,229
+0.73%
|
-
|
|
Jan 02
2024
|
Thomas J Kester Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,183
+1.18%
|
-
|
|
Jan 02
2024
|
Kathryn Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,661
+0.89%
|
-
|
|
Jan 02
2024
|
Michael Berman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,782
+1.83%
|
-
|
|
Nov 30
2023
|
Gary S Roubin Director |
BUY
Open market or private purchase
|
Direct |
50,000
+10.23%
|
$100,000
$2.53 P/Share
|
|
Oct 02
2023
|
Thomas J Kester Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,614
+0.98%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.54M shares |
|---|---|
| Open market or private purchase | 50K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 210K shares |